AEZS : Summary for Aeterna Zentaris Inc. - Yahoo Finance

U.S. Markets open in 8 hrs 21 mins

Aeterna Zentaris Inc. (AEZS)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
2.90+0.15 (+5.45%)
At close: 4:00PM EDT
People also watch
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
Previous Close2.75
Bid2.00 x 1000
Ask7.00 x 100
Day's Range2.75 - 2.92
52 Week Range2.35 - 5.59
Avg. Volume285,303
Market Cap40.34M
PE Ratio (TTM)-1.20
Earnings DateN/A
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Associated Press11 days ago

    Aeterna Zentaris reports 4Q loss

    On a per-share basis, the Montreal-based company said it had a loss of 71 cents. The drug developer posted revenue of $304,000 in the period. For the year, the company reported that its loss narrowed to ...

  • Business Wire11 days ago

    Aeterna Zentaris Reports Fourth Quarter and Full-Year 2016 Financial and Operating Results

    Aeterna Zentaris Inc. , a specialty biopharmaceutical company engaged in developing and commercializing novel treatments in oncology and endocrinology, today reported financial and operating results for the fourth quarter and year ended December 31, 2016.

  • Business Wire20 days ago

    Aeterna Zentaris Announces EMA Pediatric Committee Agreement on the Pediatric Investigation Plan for Macrilen™

    Aeterna Zentaris Inc. announced today that the Pediatric Committee of the European Medicines Agency agreed to the Company’s Pediatric Investigation Plan for Macrilen™ and agreed that the Company may defer conducting the PIP until after it files a Marketing Authorization Application seeking marketing authorization for the use of Macrilen™ for the evaluation of adult growth hormone deficiency.